# Phase 2 Clinical Trial of KH617

> **NCT07138001** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan Honghe Biotechnology Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **COMBINATION_PRODUCT:** KH617+TMZ
- **DRUG:** KH617
- **DRUG:** TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16

## Key facts

- **NCT ID:** NCT07138001
- **Lead sponsor:** Sichuan Honghe Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-09
- **Final completion:** 2030-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07138001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07138001, "Phase 2 Clinical Trial of KH617". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07138001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*